CANCER DU SEIN AVEC MÉTASTASE INHABITUELLE AU NIVEAU VÉSICAL : RAPPORT DE CAS ET REVUE SYSTÉMATIQUE DE LA LITTÉRATURE

Authors : Marcoux D, Ignatiadis M, Paesmans M, Awada A
Year : 2019
Journal : Rev Med Brux
Volume : 40(3)
Pages : 148-159

Triple negative breast cancer: current treatment and future perspectives.

Authors : El Hachem G, Jounblat Y, Awada A, Gombos A
Year : 2019
Journal : Belgian J Medical Oncology
Volume : 13(3)
Pages : 84-92

The role of direct oral anticoagulants in the management of cancer-associated thrombosis?

Authors : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Jochmans K, Mathieu V, Mebis J, Strijbos M, Vulsteke C, Vanassche T, Verhamme P
Year : 2019
Journal : Belgian J Medical Oncology
Volume : 13(3)
Pages : 84-92

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Authors : Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos P, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Year : 2018
Journal : J Clin Oncol
Volume : 36
Pages : 3007-3014

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.

Authors : Rugo HS, Cortes J, Awada A, OShaughnessey J, Twelves CJ, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri MA, Hoch U, Perez EA
Year : 2018
Journal : Clin Cancer Res
Volume : 24(14)
Pages : 3348-3357

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Authors : Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, OShaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J
Year : 2018
Journal : J Clin Oncol
Volume : 36(9)
Pages : 884-890

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

Authors : Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M
Year : 2018
Journal : Bull Cancer
Volume : 105
Pages : 842-846

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.(article)

Authors : Kotecki N, Lefranc F, Devriendt D, Awada A
Year : 2018
Journal : Ther Adv Med Oncol
Volume : 10
Pages : 1758835918780312

Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis.

Authors : El Hachem G, Jungels C, Larsimont D, Awada A
Year : 2018
Journal : Rev Med Brux
Volume : 39
Pages : 146-149

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Authors : Basaran G, Twelves C, Diéras V, Cortés J, Awada A
Year : 2018
Journal : Cancer Treat Rev
Volume : 63
Pages : 144-155

Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma. in : Luca Giovanella, Editor. Atlas of Thyroid and Neuroendocrine Tumor Markers. Springer

Authors : Costante G, Lalami Y, Jungels C, Awada A
Year : 2018
Journal : Book
Volume : -
Pages : 133-150

Precision oncology: as much expectations as limitations.

Authors : Vasconcellos VF, Colli LM, Awada A, de Castro Junior G
Year : 2018
Journal : Ecancermedicalscience
Volume : 12
Pages : ed86

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.

Authors : Maurer C, Tulpin L, Moreau M, Dumitrescu C, de Azambuja E, Paesmans M, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2018
Journal : ESMO Open
Volume : 3
Pages : e000440

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Authors : Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J
Year : 2018
Journal : Eur J Cancer
Volume : 103
Pages : 147-154

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Authors : Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem G
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 31888-31903

Tackling the challenges of brain metastases in solid tumors.

Authors : Kotecki N, Awada A
Year : 2018
Journal : Curr Opin Oncol
Volume : 30
Pages : 330-331

Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas

Authors : Closset C, Ameye L, Gebhart M, de Saint-Aubain de Somerhausen N, Beauvois S, Awada A, Piccart-Gebhart M, Gil T
Year : 2018
Journal : Int J cancer and oncology
Volume : 5(1)
Pages : 26-34

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Authors : Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2017
Journal : Front Immunol
Volume : 8
Pages : 1412

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Authors : Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF
Year : 2017
Journal : BMJ Open
Volume : 7(11)
Pages : e017075

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Authors : Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G
Year : 2017
Journal : Anticancer Res
Volume : 37
Pages : 5941-5953